DRUG STUDY

GENERIC NAME
Oxytocin Injection

CLASSIFICATION
Oxytocic

DOCTORS ORDER
Incorporate 10 units oxytocin to present IVF 1015ggts/min.

MECHANISM OF ACTION
Synthetic, watersoluble polypeptide consisting 8 amino acids, identical pharmacologicall y to the oxytocic principle of posterior pituitary

INDICATIO N
To initiate or improve uterine contraction.

CONTRAINDICATION
Hypersensitivity to oxytocin Significant cephalopelvic disproportion, unfavorable fetal position or presentations that are undeliverable without conversion during delivery. Obstetric emergencies, patients who have fetal distress, and placenta previa. Prolonged use in severe toxemia or uterine inertia, hypertonic uterine patterns. Previous surgery in uterus or cervix including cesarean section, conditions predisposing to

ADVERSE EFFECT

NURSING CARE
Start flow charts to record maternal BP, and other vital signs, I&O ratio, weight, strength, duration, and frequency of contractions as well as fetal heart tone and rate, before instituting treatment. Monitor I&O during labor. If patient is receiving drug by prolonged IV infusion, watch for symptoms of water intoxication. Report changes in alertness and orientation and changes in I & O.

Anaphylactic reactions Postpartum hemorrhage Precordial pain Edema Cyanosis CARDIOVASCUL AR Maternal cardiac arrhythmias Hypertensive episodes GASTROINTESTI NAL Nausea Vomiting CENTRAL N.S Anxiety RESPIRATORY Maternal dyspnea UROGENITAL Uterine rupture

thromboblastpin or amniotic fluid embolism.

Incidence of hypersensitivit y or allergic reactions is higher when oxytocin is given by IM or IV injection rather than infusion.

Khate Cresselle M. Galzote BSN 2

DRUG STUDY